Pembrolizumab/vibostolimab coformulation
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Sep 28, 2021 → Dec 10, 2024
NCT ID
NCT05005442About Pembrolizumab/vibostolimab coformulation
Pembrolizumab/vibostolimab coformulation is a phase 2 stage product being developed by Merck for Hematological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT05005442. Target conditions include Hematological Malignancies.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05005442 | Phase 2 | Completed |
Competing Products
20 competing products in Hematological Malignancies